CYCCP - Cyclacel Pharmaceuticals, Inc.
| Previous Close | 4.7617 |
| Open | 4.7617 |
| Bid | 0.0100 x 1100 |
| Ask | 199,999.9844 x 1200 |
| Day's Range | 4.7617 - 4.7617 |
| 52 Week Range | 4.3100 - 7.0000 |
| Volume | 75 |
| Avg. Volume | 162 |
| Market Cap | 9.054M |
| Beta (3Y Monthly) | -0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5730 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.60 (12.60%) |
| Ex-Dividend Date | 2019-07-11 |
| 1y Target Est | N/A |
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of CYC065, a CDK2/9 inhibitor, in part 3 of a Phase 1 study (CYC065-01) which is evaluating single agent CYC065 in patients with advanced solid cancers. Parts 1 and 2 of the study are evaluating CYC065 administered as an intravenous infusion. “We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 04, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel".
- Benzinga
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 07, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient in a Phase 1/2 study evaluating the safety and effectiveness of oral sapacitabine, a nucleoside analogue, in combination with oral venetoclax, a BCL2 inhibitor, in patients with relapsed or refractory AML or MDS. “Sapacitabine is an oral nucleoside analogue that is active in AML and MDS that is relapsed or refractory to prior therapy such as cytarabine or hypomethylating agents.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., May 14, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
BERKELEY HEIGHTS, N.J., April 01, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel".
- Benzinga
Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action
Penny stock Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) was sinking lower Tuesday after the nanocap biotech 's announcement concerning a paper published by independent investigators in the Journal of ...
- GlobeNewswire
Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results
BERKELEY HEIGHTS, N.J., March 20, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the 31st Annual ROTH Capital Partners Conference, which will be held March 18-19, 2019 at the Ritz-Carlton in Dana Point, California. For additional conference information or to schedule a one-on-one meeting with Cyclacel please email oneononerequests@roth.com or contact your ROTH representative.
- GlobeNewswire
Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019
BERKELEY HEIGHTS, N.J., March 05, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 05, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
"Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2018 achievements and providing an outline of the Company’s key business objectives for 2019. “At the heart of our business strategy is targeting cancer patients with overexpression of resistance pathways, including Mcl-1, and inherited mutations in DNA damage pathways, including BRCA.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™ 2019, at 9:30 a.m. PST on January 8 , in the Yosemite C (Ballroom level) at the Hilton San Francisco Union Square. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results
Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J., Nov. 12, 2018 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 06, 2018 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.